Deals Of The Week: Russia Says “Nyet” To Abbott’s Buyout Of Domestic Vaccine Company
Executive Summary
As “The Pink Sheet” team heads to BIO’s annual partnering convention in Chicago, the Russian government rejects Abbott’s bid for NGO Petrovax. Plus news on deals between Roche and Ascletis, Lilly and Siemens, and Santaris and Bristol-Myers.
You may also be interested in...
Emerging Markets Earnings Roundup: Abbott, AbbVie, J&J, GSK (Part 3)
After Abbott/AbbVie split, emerging markets represent 40% of Abbott’s sales compared to 15% of AbbVie sales. Abbott, J&J and GSK report dismal sales in Europe, noting that EMs remain a bright spot.
Lilly Expands Bet on Tau By Buying Siemens’ Alzheimer’s Imaging Portfolio
The acquisition of a tau PET imaging portfolio from Siemens further expands Lilly’s Alzheimer’s program.
Santaris, BMS Partner To Develop Therapeutics Targeting miRNA
In the latest of a handful of big pharma RNA partnerships, Bristol-Myers and Santaris have entered into a broad discovery and development deal. For the biotech, it brings a new partner into the string of deals that continue to be its main source of capital.